Real-world evidence solutions market is anticipated to grow at a CAGR of 12.40% during the forecast period (2024-2031). The market’s growth is attributed to the growing demand for healthcare industry is prioritizing patient-centric approaches, aiming for faster and more efficient clinical trials to expedite access to innovative treatments for patients. For instance, in June 2023, Verana Health launched VeraSite, a subscription-based tool for identifying potential clinical trial sites. The tool allows sponsors and CROs to quickly identify practices with clinical expertise and patient populations, guiding site selection and allowing direct contact with practices of interest.
Segmental Outlook
The global real-world evidence solutions market is segmented by component, application, and end user. Based on the component, the market is sub-segmented into services, and data sets.. Based on the application, the market is sub-segmented intodrug development and approvals, post-market surveillance, market access reimbursement/cover end-user decision making, and clinical and regulatory decision-making. Furthermore, based on end users, the market is sub-segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and others.The pharmaceutical and medical device companies’ subcategory is expected to capture a significant portion of the market share within the end-user segment. The growth can be attributed to the increasing importance of real world evidence (RWE) studies are increasingly crucial in drug approval, real-world performance assessment, and preventing recalls, aiding in patient benefit identification, regulatory approvals, reimbursement, and increased indications of use.
Oncology Sub-Sub-Segment is Anticipated to Hold a Considerable Share of the Global Real-World Evidence Solutions Market
Among the applications, the oncology sub-sub-segment is expected to hold a considerable share of the global real-world evidence solutions market. The segmental growth is attributed to the growing emphasis for data-driven decision-making in cancer research and treatment, reflecting wider industry trends. Furthermore, the market players are looking for the new product launch to meet the demand for the solutions. For instance, in May 2023, Flatiron Health expanded into oncology real-world evidence generation. Its Integrated real-world evidence (RWE) Solutions approach allows partners to generate strong RWE and insights. It enables Flatiron to become a 'one-stop-shop' for oncology RWD/E development across the product lifecycle, hence enhancing cancer patient experiences.
Regional Outlook
The global real-world evidence solutions market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the growing number of elderly individuals and the higher occurrence of cancer and chronic illnesses in the region, additionally there has been an increase in demand for healthcare services.
Global Real-World Evidence Solutions Market Growth, by Region 2024-2031
The North American region is Expected to Grow at a Significant CAGR in the global Real-World Evidence Solutions Market
Among all regions, the North American region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing availability of high-quality real-world data sources such as wearables, healthcare apps, and electronic health records. . According to the National Institute og Health (gov.), in October 2023, the publication provides an updated review of the global regulatory landscape for leveraging real-world evidence (RWE) in healthcare. It evaluates the availability of frameworks, guidance, data quality, study methods, and procedural guidance in different regions. The review also highlights gaps and potential opportunities for future development and harmonization, as well as the alignment among regulators and health technology assessment (HTA) bodies in utilizing RWE.
Market Players Outlook
The major companies serving the global real-world evidence solutions market include Dassault Systèmes S.E., IBM Corp., Oracle, PerkinElmer Inc., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2023, Thermo Fisher Scientific Inc. acquired CorEvitas, LLC, focusing on real-world evidence collection and use in routine clinical care, a high-growth market segment for pharmaceutical and biotechnology customers.
In December 2023, BC Platforms acquired Medexprim, expanding its capability to offer global biopharma partners secure access to real-world clinical and imaging data assets.
The Report Covers
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. Cegedim Health
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Clinigen Ltd.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Cognizant Technology Solutions Corp.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Key Strategy Analysis
4. Market Segmentation
4.1. Global Real-World Evidence Solutions Market by Component
4.1.1. Services
4.1.2. Data Sets
4.1.2.1. Disparate Data Sets
4.1.2.2. Integrated Data Sets
4.2. Global Real-World Evidence Solutions Market by Application
4.2.1. Drug Development and Approvals
4.2.2. Post-Market Surveillance
4.2.3. Market Access Reimbursement/Cover End-User Decision Making
4.2.4. Clinical and Regulatory Decision-Making
4.3. Global Real-World Evidence Solutions Market by End-User
4.3.1. Pharmaceutical & Medical Device Companies
4.3.2. Healthcare Providers
4.3.3. Healthcare Payers
4.3.4. Others (Patients and Patient Advocacy Groups, Research Organizations and Academia)
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Dassault Systèmes S.E.
6.2. Flatiron Health
6.3. IBM Corp.
6.4. ICON plc.
6.5. India Medtronic Pvt. Ltd.
6.6. IQVIA, Inc.
6.7. Optum, Inc.
6.8. Oracle
6.9. Parexel International Corp.
6.10. PerkinElmer Inc.
6.11. Real Endpoints
6.12. Saama Technologies, LLC.
6.13. SAS Institute Inc.
6.14. Syneos Health
6.15. Thermo Fisher Scientific Inc.
6.16. TriNetX LLC
1. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
2. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
3. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DATA SETS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
4. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
5. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
6. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN POST-MARKET SURVEILLANCE MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
7. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN ACCESS REIMBURSEMENT/COVER END USER DECISION MAKING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
8. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CLINICAL AND REGULATORY DECISION-MAKING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
9. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
10. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
11. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PROVIDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
12. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PAYERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
13. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
14. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
15. NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
16. NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
17. NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
18. NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
19. EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
20. EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
21. EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
22. EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
23. ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
24. ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
25. ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
26. ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
27. REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
28. REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
29. REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
30. REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
1. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY COMPONENT, 2023 VS 2031 (%)
2. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY SERVICES MARKET SHARE BY REGION, 2023 VS 2031 (%)
3. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
4. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DISPARATE DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
5. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY INTEGRATED DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
6. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY APPLICATION, 2023 VS 2031 (%)
7. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
8. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN ONCOLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
9. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN NEUROLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
10. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN IMMUNOLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
11. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CARDIOVASCULAR DISEASE MARKET SHARE BY REGION, 2023 VS 2031 (%)
12. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN OTHER THERAPEUTIC AREAS MARKET SHARE BY REGION, 2023 VS 2031 (%)
13. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN MEDICAL DEVICE DEVELOPMENT AND APPROVALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
14. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN POST-MARKET SURVEILLANCE MARKET SHARE BY REGION, 2023 VS 2031 (%)
15. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN MARKET ACCESS REIMBURSEMENT/COVERAGE DECISION MAKING MARKET SHARE BY REGION, 2023 VS 2031 (%)
16. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CLINICAL AND REGULATORY DECISION-MAKING MARKET SHARE BY REGION, 2023 VS 2031 (%)
17. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY END-USER, 2023 VS 2031 (%)
18. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES MARKET SHARE BY REGION, 2023 VS 2031 (%)
19. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PROVIDERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
20. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PAYERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
21. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR OTHERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
22. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY REGION, 2023 VS 2031 (%)
23. US REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
24. CANADA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
25. UK REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
26. FRANCE REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
27. GERMANY REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
28. ITALY REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
29. SPAIN REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
30. REST OF EUROPE REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
31. INDIA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
32. CHINA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
33. JAPAN REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
34. SOUTH KOREA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
35. REST OF ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
36. REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)